Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Adaptive Biotechnologies Corp (DE:1HM)
FRANKFURT:1HM
RESEARCH TOOLSreports
Adaptive Biotechnologies (1HM) Stock Price & Analysis
1 Followers
1HM Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€2.15 - €8.41
Previous Close€2.32
Volume0.00
Average Volume (3M)465.00
Market Cap
€349.50M
Enterprise Value€239.73M
Total Cash (Recent Filing)$346.40M
Total Debt (Recent Filing)$229.43M
Price to Earnings (P/E)N/A
Beta1.65
Next Earnings
May 07, 2024EPS Estimate
-€0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding145,092,271
10 Day Avg. Volume220
30 Day Avg. Volume465
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)2.03
Price to Sales (P/S)1.98
Price to Cash Flow (P/CF)-3.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.41
Enterprise Value/Gross Profit2.53
Enterprise Value/Ebitda-1.62
Forecast
1Y Price Target
€5.98Price Target Upside151.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Adaptive Biotechnologies News
PremiumCompany Announcements
Adaptive Biotechnologies Names Kyle Piskel New CFO
PremiumCompany Announcements
Adaptive Biotechnologies CFO Resigns, Successor Appointed
Bulls Say, Bears Say
Bulls Say
Financial PerformanceADPT pre-announced revenues above expectations, indicating stronger than expected financial performance.
Market LeadershipADPT owns the blood-based MRD testing space in the clinic and with pharma, and is a valuable strategic asset in the market.
Strategic Business DecisionConclusion of strategic review results in the company keeping the MRD and IM businesses separate within ADPT, while implementing dedicated resources and segment reporting structures for each.
Bears Say
Financial PerformanceADPT reported a Q4 top-line miss with revenue of $45.8M, a decline of 17% year-over-year.
Leadership ChangesCFO Tycho Peterson to depart for another opportunity, to be succeeded by ADPT's current Principal Accounting Officer, Kyle Piskel.
Revenue Forecast2024 guidance comes in below MRD forecasts, despite strong ASP expectations.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
12.42% Other Institutional Investors
87.58% Public Companies and
Individual Investors
1HM FAQ
What was Adaptive Biotechnologies Corp’s price range in the past 12 months?
Adaptive Biotechnologies Corp lowest stock price was €2.15 and its highest was €8.41 in the past 12 months.
What is Adaptive Biotechnologies Corp’s market cap?
Currently, no data Available
When is Adaptive Biotechnologies Corp’s upcoming earnings report date?
Adaptive Biotechnologies Corp’s upcoming earnings report date is May 07, 2024 which is in 11 days.
How were Adaptive Biotechnologies Corp’s earnings last quarter?
Adaptive Biotechnologies Corp released its earnings results on Feb 14, 2024. The company reported -€0.45 earnings per share for the quarter, missing the consensus estimate of -€0.31 by -€0.14.
Is Adaptive Biotechnologies Corp overvalued?
According to Wall Street analysts Adaptive Biotechnologies Corp’s price is currently Undervalued.
Does Adaptive Biotechnologies Corp pay dividends?
Adaptive Biotechnologies Corp does not currently pay dividends.
What is Adaptive Biotechnologies Corp’s EPS estimate?
Adaptive Biotechnologies Corp’s EPS estimate is -€0.32.
How many shares outstanding does Adaptive Biotechnologies Corp have?
Currently, no data Available
What happened to Adaptive Biotechnologies Corp’s price movement after its last earnings report?
Adaptive Biotechnologies Corp reported an EPS of -€0.45 in its last earnings report, missing expectations of -€0.31. Following the earnings report the stock price went down -4.172%.
Which hedge fund is a major shareholder of Adaptive Biotechnologies Corp?
Among the largest hedge funds holding Adaptive Biotechnologies Corp’s share is Viking Global Investors LP. It holds Adaptive Biotechnologies Corp’s shares valued at 147M.
---
Adaptive Biotechnologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€5.98 (151.24% Upside)
€5.98 (151.24% Upside)
Blogger Sentiment
Neutral
DE:1HM Sentiment 50%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $12.6K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-68.48%
12-Months-Change
Fundamentals
Return on Equity
-58.31%
Trailing 12-Months
Asset Growth
-22.82%
Trailing 12-Months
Company Description
Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. It harnesses the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson in September 2009 and is headquartered in Seattle, WA.
---
1HM Company Deck
---
1HM Earnings Call
Q4 2024
0:00 / 0:00
---
1HM Stock 12 Months Forecast
Average Price Target
€5.98
▲(151.24% Upside)
Technical Analysis
Adaptive Biotechnologies
―
Arcturus Therapeutics
―
BioCryst
―
Crispr Therapeutics AG
―
Editas Medicine
―
Best Analysts Covering 1HM
1 Year
1 Year Success Rate
0/9 ratings generated profit
1 Year Average Return
-36.66%
assigned a buy rating 2 months ago
Copying David Westenberg's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -36.66% per trade.
---